{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'reports, or autopsy reports) in order to perform an independent medical assessment of the', 'reported case.', '7.4.5.5', 'Follow-up of Serious Adverse Events by the Investigator', 'Any SAEs that occur at or after Visit 1 (OLE Baseline/Week 24) until the end of the Safety', 'Follow-Up Period (i.e., 22 weeks after the last dose of study treatment) regardless of the', \"Investigator's opinion of causality, will be followed up. The Investigator should follow each\", 'SAE until the event has resolved to the baseline grade or better, the event is assessed as', 'stable by the Investigator, the subject is lost to follow-up, or the subject withdraws consent.', \"If the subject is lost to follow-up, the SAE will be categorized based on the Investigator's last\", 'assessment. Every effort should be made to follow all SAEs considered to be related to OKZ', 'or study-related procedures until an outcome can be reported.', 'During the study, resolution of SAEs (with dates) should be documented on the SAE page of', \"the eCRF and in the subject's medical record to facilitate source data verification. If, after\", 'follow-up, return to the baseline status or stabilization cannot be established, an explanation', 'should be recorded on the SAE page of the eCRF.', 'All pregnancies reported during the study should be followed until pregnancy outcome.', '7.4.6', 'Clinical Laboratory Evaluations', 'Clinical laboratory tests will be reviewed for results of potential clinical significance at all', 'time points throughout the study. The Investigator will evaluate any change in laboratory', 'values. If the Investigator determines a laboratory abnormality to be clinically significant, it', 'is considered a laboratory AE; however, if the abnormal laboratory value is consistent with a', 'current diagnosis (or signs or symptoms if a diagnosis is not possible) and is not a clinically', 'significant worsening from the baseline laboratory parameter, it should be documented', 'accordingly without being reported as a separate laboratory AE. The central laboratory will', 'analyze the samples. Further details of the procedures to be followed for sample collection,', 'storage, and shipment will be documented in a Laboratory Manual. Additional and repeat', 'laboratory testing not specified in Table 1 may be performed at the discretion of the', 'Investigator to ensure that the safety of subjects is protected.', '7.4.6.1', 'Laboratory Parameters', 'Unless otherwise noted, the central laboratory will be used in this study to analyze routine', 'blood samples. Blood samples will be collected according to the study Schedule of Events in', 'Table 1.', 'CRP', 'Amendment 2: 06 March 2019', '112', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'ESR: Blood for ESR will be obtained at scheduled visits and tested locally.', 'Hematology: Red blood cell count, total and differential white blood cell count,', 'hemoglobin, hematocrit, and platelet count', 'INR, aPTT, and fibrinogen', 'Chemistry panel: Urea nitrogen, creatinine, fasting glucose, calcium, sodium,', 'potassium, chloride, total protein, total bilirubin, direct bilirubin, indirect bilirubin,', 'ALT, AST, alkaline phosphatase, GGT, and albumin', 'HbA1c is required only for subjects with a confirmed diagnosis of diabetes mellitus.', 'Urinary pregnancy testing (human chorionic gonadotropin) is required only for women', 'who are of childbearing potential. Urinary pregnancy testing will be conducted locally', 'using dipsticks provided by the central laboratory. Pregnancy testing may be repeated', 'more frequently than specified in Table 1 (i.e., between study visits) if required by', 'local practices, IRB/IECs or local regulations, or as deemed necessary by Investigator.', 'If more frequent testing is required, the study site will provide the patient with further', 'guidance and testing kit.', 'Urinalysis: Specific gravity, pH, protein, glucose, ketones, blood, and leukocyte', 'esterase', 'Lipid panel: Total cholesterol, HDL, LDL, triglycerides, lipoprotein (a),', 'apolipoproteins (apolipoprotein B [ApoB], apolipoprotein Al [ApoA1], and', 'ApoB:ApoAl ratio), and adiponectin', 'Cardiovascular risk panel: N-terminal pro-hormone of brain natriuretic peptide', '(NT-proBNP), brain natriuretic peptide (BNP), and homocysteine', 'IGRA', '-', 'All subjects who had a negative IGRA result at Screening of the core study will have', 'an IGRA performed at Week 22 of the core study (2 weeks prior to OLE Baseline),', \"and the result is to be known prior to OLE Baseline to determine the subject's\", 'eligibility for the OLE study (see exclusion criterion No. 3 in Section 5.3.2).', '-', 'For all post-OLE Baseline visits where IGRA is scheduled, the test will be performed', 'only for subjects who had a negative IGRA result at the previous assessments', '(including Week 22 assessment of the core study) unless another approach is required', 'by local practice. If results are indeterminate, the IGRA can be repeated once.', '-', 'Details of the assessment are provided in the Laboratory Manual.', 'Amendment 2: 06 March 2019', '113', 'Confidential']\n\n###\n\n", "completion": "END"}